Paying For Gene Therapy: Medicaid Will Be ‘Canary In Coal Mine’
Executive Summary
Harvard Pilgrim's Michael Sherman and Cigna's Steve Miller advise gene therapy developers to consider the burden of high cost treatments on Medicaid programs when setting list prices.
You may also be interested in...
Calls For National Tech Assessment Program Could Be Amplified By Costs Of Cell, Gene Therapy
Speculation is growing that the Institute for Clinical and Economic Review or something like it could become the US version of the government-sponsored health tecnology assessment bodies in Europe.
Curative Gene Therapy Coverage May Need Government-Funded Risk Pools
Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.
Employers Would ‘Welcome’ Government Role In Covering High-Cost Therapies
Annual large employer health benefits survey for 2020 and beyond finds support for government price negotiation and payment through a national fund. Plans to expand point-of-sale rebates and coupon accumulator programs also reported.